IMR Press / EJGO / Volume 26 / Issue 4 / pii/2005192

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Loss of basement membrane heparan sulfate expression is associated with tumor progression in endometrial cancer

Show Less
1 Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine and Dentistry, Okayama (Japan)
Eur. J. Gynaecol. Oncol. 2005, 26(4), 403–406;
Published: 10 August 2005
Abstract

Perlecan is a major heparan sulfate proteoglycan (HPSG) of the basement membrane (BM) and binds to various cytokines and growth factors via its heparan sulfate glycosaminoglycan (HS-GAG) chains. The aim of this study was to investigate BM HS-GAG expression in endometrial cancers. We investigated the expression of BM HS-GAG by immunohistochemistry in I 09 endometrial cancers and analyzed correlations with various clinicopathological features. The HS-GAG expression index was significantly lower in cases of advanced stage, high-grade, deep myometrial invasion, positive peritoneal cytology, lymph vascular space invasion and lymph node metastasis. There was no association between HS-GAG expression status and patient outcome. Decreased HS-GAG expression of BM is associated with tumor progression, but is not be a useful prognostic factor in patients presenting with endome­trial cancer.

Keywords
Heparan sulfate
Basement membrane
Endometrial cancer
Share
Back to top